Company / Depreciation & Amortization
Avalo Therapeutics, Inc. Depreciation & Amortization History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$344.0K
FY2025
5-year range
$158.0K / $1.7M
FY2021-FY2025
Trend
+103.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $158,000 to $344,000 over the past 2 years.
Based on SEC 10-K filings.
$344,000 in FY2025 with a 5-year CAGR of -28.5%.
Increased from $158,000 to $344,000 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +27.5%
- 5-Year CAGR
- -28.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -28.5%, indicating a declining trend.
- In FY2025, depreciation & amortization increased 103.6% year-over-year.
- Peak depreciation & amortization was recorded in FY2018.
- Lowest depreciation & amortization in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $344.0K | +103.6% |
| FY2024 | $169.0K | +7.0% |
| FY2023 | $158.0K | -4.8% |
| FY2022 | $166.0K | -90.0% |
| FY2021 | $1.7M | -10.1% |
| FY2020 | $1.8M | -52.5% |
| FY2019 | $3.9M | -14.7% |
| FY2018 | $4.6M | +970.6% |
| FY2017 | $425.5K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026